Neos Therapeutics at Wells Fargo Securities Healthcare Conference (Live)
09/08/16 at 9:55 a.m. ET
Corporate ProfileNeos Therapeutics is focused on developing, manufacturing and commercializing branded products utilizing our proprietary extended-release drug delivery technology platform. We have used this technology to develop our three product candidates being investigated for the treatment of attention deficit hyperactivity disorder, or ADHD. Our ADHD product candidates are extended-release, or XR, medications in patient-friendly, orally disintegrating tablets, or ODT, or liquid suspension dosage forms.
- 08/31/16Neos Therapeutics to Present at the Wells Fargo Securities Healthcare Conference on September 8, 2016
- 08/11/16Neos Therapeutics Announces Second Quarter 2016 Financial Results
- 08/02/16Neos Therapeutics to Host Second Quarter 2016 Financial Results Conference Call on August 11, 2016
- 07/28/16Neos Therapeutics Announces Successful Completion of Bioequivalence Bridging Study for Cotempla XR-ODT™ (Methylphenidate Extended-Release Orally Disintegrating Tablet)